After H.C. Wainwright and Guggenheim gave Krystal Biotech Inc (NASDAQ: KRYS) a Buy rating last month, the company received another Buy, this time from Chardan Capital. Analyst Gbola Amusa reiterated a Buy rating on Krystal Biotech Inc today and set a price target of $57.50. The company’s shares opened today at $31.65.
Amusa wrote:
“We conservatively model $46 mm in risk-adjusted 2030E sales and $2.25 NPV/share for KB105, meaning KB105 could become a future driver of Chardan KRYS price target upgrades, with any KB105 clinical progress.”
According to TipRanks.com, Amusa is a 5-star analyst with an average return of 18.5% and a 52.1% success rate. Amusa covers the Healthcare sector, focusing on stocks such as Logicbio Therapeutics Inc, Axovant Gene Therapies, and Crispr Therapeutics AG.
Currently, the analyst consensus on Krystal Biotech Inc is a Strong Buy with an average price target of $44.38, representing a 40.2% upside. In a report issued on May 30, Guggenheim also initiated coverage with a Buy rating on the stock with a $48 price target.
See today’s analyst top recommended stocks >>
Based on Krystal Biotech Inc’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $4.11 million. In comparison, last year the company had a GAAP net loss of $2.15 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Krystal Biotech, Inc. is a gene therapy company, which engages in developing and commercializing treatment for patients suffering from dermatological diseases. It developed a gene therapy platform, which company refer to as the Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes simplex virus 1, or HSV-1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases for which company believe there are no known effective treatments. The company was founded by Suma M. Krishnan in December 2017 and is headquartered in Pittsburgh, PA.
